BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28978268)

  • 1. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
    Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
    Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
    J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells.
    Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX
    Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
    Zhong J; Zhang J; Yu X; Zhang X; Dian L
    Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
    Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
    Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression.
    Li H; Hui L; Xu W; Shen H; Chen Q; Long L; Zhu X
    Pharm Biol; 2012 Oct; 50(10):1233-40. PubMed ID: 22957792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes.
    Kim KY; Cho HS; Jung WH; Kim SS; Cheon HG
    Mol Pharmacol; 2007 Jun; 71(6):1554-62. PubMed ID: 17337625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Ji BS; He L; Liu GQ
    Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.
    Cao LQ; Chen XL; Wang Q; Huang XH; Zhen MC; Zhang LJ; Li W; Bi J
    Acta Pharmacol Sin; 2007 Jun; 28(6):879-87. PubMed ID: 17506947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone.
    Chen Q; Zhou J; Jiang C; Chen J
    J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):326-31. PubMed ID: 20556576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
    Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
    Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
    Zhang H; Jing X; Wu X; Hu J; Zhang X; Wang X; Su P; Li W; Zhou G
    Anticancer Drugs; 2015 Aug; 26(7):706-15. PubMed ID: 26053275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.